Routine COVID-19 testing may not be necessary for most cancer patients
Abstract Cancer patients are at risk for severe complications or death from COVID-19 infection. Therefore, the need for routine COVID-19 testing in this population was evaluated. Between 1st August and 30th October 2020, 150 cancer patients were included. Symptoms of COVID-19 infection were evaluate...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/16e1e55e3ed04ae9b99abd7dbca14de7 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:16e1e55e3ed04ae9b99abd7dbca14de7 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:16e1e55e3ed04ae9b99abd7dbca14de72021-12-05T12:15:31ZRoutine COVID-19 testing may not be necessary for most cancer patients10.1038/s41598-021-02692-32045-2322https://doaj.org/article/16e1e55e3ed04ae9b99abd7dbca14de72021-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-02692-3https://doaj.org/toc/2045-2322Abstract Cancer patients are at risk for severe complications or death from COVID-19 infection. Therefore, the need for routine COVID-19 testing in this population was evaluated. Between 1st August and 30th October 2020, 150 cancer patients were included. Symptoms of COVID-19 infection were evaluated. All eligible individuals went through RT-PCR and serological tests for COVID-19. At the same time, 920 non-cancer patients were recruited from a random sample of individuals who were subject to routine molecular and anti-body screening tests. Of 150 cancer patients, 7 (4.7%) were RT-PCR positive. Comorbidity made a significant difference in the RT-PCR positivity of cancer patients, 71.4% positive versus 25.8% negative (P-value = 0.02). The average age for negative and positive groups was 53.3 and 58.2 respectively (P-value = 0.01). No significant difference was observed between cancer and non-cancer patients regarding COVID-19 antibody tests. However, cancer patients were 3 times less likely to have a positive RT-PCR test result OR = 0.33 (CI: 0.15–0.73). The probability of cancer patients having a positive routine test was significantly lower than non-cancer patients, and the concept that all cancer patients should be routinely tested for COVID-19 may be incorrect. Nevertheless, there may be a subgroup of patients with comorbidities or older age who may benefit from routine COVID-19 testing. Importantly, these results could not be subjected to multivariate analysis.Ali MotlaghFatemeh ElmiMaisa YamraliMansour RanjbarMehrdad AzminFarzaneh MoshiriChristoph HamelmannSlim SlamaNadia TavakoliAsmus HammerichNasim PourghazianMarzeyeh Soleymani NejadAhmad MafiPayam AzadehMaryam AghajanizadehAfshin OstovarAlireza RaeisiReza MalekzadehNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Ali Motlagh Fatemeh Elmi Maisa Yamrali Mansour Ranjbar Mehrdad Azmin Farzaneh Moshiri Christoph Hamelmann Slim Slama Nadia Tavakoli Asmus Hammerich Nasim Pourghazian Marzeyeh Soleymani Nejad Ahmad Mafi Payam Azadeh Maryam Aghajanizadeh Afshin Ostovar Alireza Raeisi Reza Malekzadeh Routine COVID-19 testing may not be necessary for most cancer patients |
| description |
Abstract Cancer patients are at risk for severe complications or death from COVID-19 infection. Therefore, the need for routine COVID-19 testing in this population was evaluated. Between 1st August and 30th October 2020, 150 cancer patients were included. Symptoms of COVID-19 infection were evaluated. All eligible individuals went through RT-PCR and serological tests for COVID-19. At the same time, 920 non-cancer patients were recruited from a random sample of individuals who were subject to routine molecular and anti-body screening tests. Of 150 cancer patients, 7 (4.7%) were RT-PCR positive. Comorbidity made a significant difference in the RT-PCR positivity of cancer patients, 71.4% positive versus 25.8% negative (P-value = 0.02). The average age for negative and positive groups was 53.3 and 58.2 respectively (P-value = 0.01). No significant difference was observed between cancer and non-cancer patients regarding COVID-19 antibody tests. However, cancer patients were 3 times less likely to have a positive RT-PCR test result OR = 0.33 (CI: 0.15–0.73). The probability of cancer patients having a positive routine test was significantly lower than non-cancer patients, and the concept that all cancer patients should be routinely tested for COVID-19 may be incorrect. Nevertheless, there may be a subgroup of patients with comorbidities or older age who may benefit from routine COVID-19 testing. Importantly, these results could not be subjected to multivariate analysis. |
| format |
article |
| author |
Ali Motlagh Fatemeh Elmi Maisa Yamrali Mansour Ranjbar Mehrdad Azmin Farzaneh Moshiri Christoph Hamelmann Slim Slama Nadia Tavakoli Asmus Hammerich Nasim Pourghazian Marzeyeh Soleymani Nejad Ahmad Mafi Payam Azadeh Maryam Aghajanizadeh Afshin Ostovar Alireza Raeisi Reza Malekzadeh |
| author_facet |
Ali Motlagh Fatemeh Elmi Maisa Yamrali Mansour Ranjbar Mehrdad Azmin Farzaneh Moshiri Christoph Hamelmann Slim Slama Nadia Tavakoli Asmus Hammerich Nasim Pourghazian Marzeyeh Soleymani Nejad Ahmad Mafi Payam Azadeh Maryam Aghajanizadeh Afshin Ostovar Alireza Raeisi Reza Malekzadeh |
| author_sort |
Ali Motlagh |
| title |
Routine COVID-19 testing may not be necessary for most cancer patients |
| title_short |
Routine COVID-19 testing may not be necessary for most cancer patients |
| title_full |
Routine COVID-19 testing may not be necessary for most cancer patients |
| title_fullStr |
Routine COVID-19 testing may not be necessary for most cancer patients |
| title_full_unstemmed |
Routine COVID-19 testing may not be necessary for most cancer patients |
| title_sort |
routine covid-19 testing may not be necessary for most cancer patients |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/16e1e55e3ed04ae9b99abd7dbca14de7 |
| work_keys_str_mv |
AT alimotlagh routinecovid19testingmaynotbenecessaryformostcancerpatients AT fatemehelmi routinecovid19testingmaynotbenecessaryformostcancerpatients AT maisayamrali routinecovid19testingmaynotbenecessaryformostcancerpatients AT mansourranjbar routinecovid19testingmaynotbenecessaryformostcancerpatients AT mehrdadazmin routinecovid19testingmaynotbenecessaryformostcancerpatients AT farzanehmoshiri routinecovid19testingmaynotbenecessaryformostcancerpatients AT christophhamelmann routinecovid19testingmaynotbenecessaryformostcancerpatients AT slimslama routinecovid19testingmaynotbenecessaryformostcancerpatients AT nadiatavakoli routinecovid19testingmaynotbenecessaryformostcancerpatients AT asmushammerich routinecovid19testingmaynotbenecessaryformostcancerpatients AT nasimpourghazian routinecovid19testingmaynotbenecessaryformostcancerpatients AT marzeyehsoleymaninejad routinecovid19testingmaynotbenecessaryformostcancerpatients AT ahmadmafi routinecovid19testingmaynotbenecessaryformostcancerpatients AT payamazadeh routinecovid19testingmaynotbenecessaryformostcancerpatients AT maryamaghajanizadeh routinecovid19testingmaynotbenecessaryformostcancerpatients AT afshinostovar routinecovid19testingmaynotbenecessaryformostcancerpatients AT alirezaraeisi routinecovid19testingmaynotbenecessaryformostcancerpatients AT rezamalekzadeh routinecovid19testingmaynotbenecessaryformostcancerpatients |
| _version_ |
1718372060087975936 |